Table of Content - Lung Cancer Therapeutics Market Size, Trends Analysis 2032

Lung Cancer Therapeutics Market Segmentation

Lung Cancer Therapeutics Type Outlook (USD Billion, 2018-2030)

SCLC

NSCLC

Lung Cancer Therapeutics Treatment Outlook (USD Billion, 2018-2030)

Surgery

Chemotherapy

Radiotherapy

Photodynamic Therapy (PDT)

Laser Therapy

Lung Cancer Therapeutics End-User Outlook (USD Billion, 2018-2030)

Hospital & Clinics

Cancer Research Centers and Laboratories

Lung Cancer Therapeutics Regional Outlook (USD Billion, 2018-2030)

North America Outlook (USD Billion, 2018-2030)
- North America Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- North America Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- North America Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- US Outlook (USD Billion, 2018-2030)
- US Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- US Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- US Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- Canada Outlook (USD Billion, 2018-2030)
- Canada Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- Canada Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- Canada Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories

Europe Outlook (USD Billion, 2018-2030)
- Europe Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- Europe Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- Europe Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- Germany Outlook (USD Billion, 2018-2030)
- Germany Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- Germany Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- Germany Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- France Outlook (USD Billion, 2018-2030)
- France Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- France Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- France Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- UK Outlook (USD Billion, 2018-2030)
- UK Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- UK Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- UK Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- Italy Outlook (USD Billion, 2018-2030)
- Italy Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- Italy Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- Italy Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- Spain Outlook (USD Billion, 2018-2030)
- Spain Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- Spain Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- Spain Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- Rest Of Europe Outlook (USD Billion, 2018-2030)
- Rest Of Europe Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- Rest Of Europe Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- Rest Of Europe Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories

Asia-Pacific Outlook (USD Billion, 2018-2030)
- Asia-Pacific Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- Asia-Pacific Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- Asia-Pacific Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- China Outlook (USD Billion, 2018-2030)
- China Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- China Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- China Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- Japan Outlook (USD Billion, 2018-2030)
- Japan Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- Japan Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- Japan Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- India Outlook (USD Billion, 2018-2030)
- India Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- India Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- India Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- Australia Outlook (USD Billion, 2018-2030)
- Australia Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- Australia Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- Australia Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)
- Rest of Asia-Pacific Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- Rest of Asia-Pacific Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- Rest of Asia-Pacific Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories

Rest of the World Outlook (USD Billion, 2018-2030)
- Rest of the World Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- Rest of the World Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- Rest of the World Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- Middle East Outlook (USD Billion, 2018-2030)
- Middle East Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- Middle East Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- Middle East Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- Africa Outlook (USD Billion, 2018-2030)
- Africa Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- Africa Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- Africa Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories
- Latin America Outlook (USD Billion, 2018-2030)
- Latin America Lung Cancer Therapeutics by Type
  - SCLC
  - NSCLC
- Latin America Lung Cancer Therapeutics by Treatment
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Photodynamic Therapy (PDT)
  - Laser Therapy
- Latin America Lung Cancer Therapeutics by End-User
  - Hospital & Clinics
  - Cancer Research Centers and Laboratories

Research Methodology on Lung Cancer Market

Introduction

The global lung cancer market is expected to experience significant growth over the forecast period between 2023 and 2030 driven by the increasing prevalence of cancer, technological advancements in diagnosis and treatment processes and the availability of effective therapeutic approaches. This report aims to analyze the current prospects of the market, overview the key technological advancements, and review the innovative treatment strategies and strategies adopted by major players to increase their market potential.

Research Methodology

The research for this report is conducted using a combination of qualitative and quantitative research methods, including both primary and secondary research. The primary research involves in-depth interviews and questionnaires with major players in the field, as well as other industry experts, to gain insider insights and perceptions on the latest technological advancements, market trends, and investment strategies of players in the global lung cancer market. Secondary research entailed collecting data from a range of sources including industry databases, government websites and reports, market reports, leading journals and other relevant literature.

A comprehensive market analysis comprising the macro and micro factors influencing the demand, supply, and outlook of the global lung cancer market was conducted. The market size and CAGR for the forecast period of 2023 to 2030 are determined based on the trend analysis of various factors, such as market dynamics, technological advancements, and competitive strategy analysis. A complete analysis of the competitive scenario is also carried out to identify the major players and their market positions.

In addition, Porter’s Five Forces analysis was conducted to analyze the competitive landscape. This is done to identify the major suppliers and purchasers, their capabilities and limitations, their market strategy and the threats prevalent in the lung cancer market. SWOT analysis was conducted to assess the strengths and weaknesses of the business, the opportunities present, and the potential threats that may hinder the growth of the market.

Furthermore, market simulations were undertaken to evaluate the future growth potential of the lung cancer market. The results of these simulations were used to forecast the CAGR for the period 2023-2030. Additionally, a value chain analysis and PESTLE analysis were conducted to provide a better understanding of the growth prospects of the global lung cancer market and the various factors influencing its growth.

Lastly, other quantitative research was conducted to develop a better appreciation of the market dynamics and their effects on the market segments. The research incorporated data triangulation, corroboration analysis, and market sizing. The information gathered through this approach was combined with insights gleaned from the qualitative research to gain a deeper understanding of the industry.

Conclusion

This report provides a comprehensive overview of the current and future prospects of the global lung cancer market, comprising the various drivers and restraints influencing the market, the key technological advancements, and the strategies adopted by leading players. It further provides the market size, CAGR and a comprehensive macro and micro market analysis, including a comprehensive value chain analysis, Porter’s Five Forces analysis and a PESTLE analysis. The research was carried out using a combination of qualitative and quantitative research methods to gain a deeper understanding of the market’s current and future prospects.

Leading companies partner with us for data-driven Insights

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

1 Report Prologue

2 Introduction

2.1 Pipeline Development 15

2.2 Research Objective 21

2.3 Assumptions & Limitations 22

2.3.1 Assumptions 22

2.3.2 Limitations 22

2.4 Market Structure 22

3 Research Methodology

3.1 Primary Research 24

3.2 Secondary Research 24

4 Porter’s Five Forces

4.1 Introduction 25

4.2 Bargaining Power of Buyers 26

4.3 Bargaining Power of Suppliers 26

4.3.1 Threat from Substitute 26

4.3.2 Threat from a New Entrant 26

4.3.3 Intensity of Competitive Rivalry 26

5 Market Dynamics

5.1 Drivers 28

5.1.1 Smoking 28

5.1.2 Environmental Pollution 28

5.1.3 Rising Cases of Infections 28

5.1.4 Growing Rates of Early Detection and Awareness 28

5.1.5 Rising Rates of Fast Growing Lung Cancer 29

5.1.6 Reimbursements and Growing Health Insurance 29

5.2 Restraints 29

5.2.1 Poor Efficacy, Cure Rates, and Side Effects of Present Treatment 29

5.2.2 High Failure Rates of Lung Transplant Surgeries 29

5.2.3 High Malignant Nature and Faster Growth of Lung Cancer 29

5.2.4 Poor Life Expectancy and Quality of Life of Patients Undergoing Lung Cancer Treatment 30

5.2.5 Loss of Patents of Lung Cancer Drugs 30

5.2.6 Scarcity of Lung Organ and Long Waiting Lines 30

5.3 Opportunities 30

5.3.1 Rising Research and Development 30

5.3.2 Huge Market 30

5.3.3 Rising Support from Public and Philanthropic Bodies and Increasing Collaboration will Help to Drive Down the Development Cost 30

5.3.4 Targeted and Genetic Therapies 31

5.4 Technological Trends and Advancements 31

5.4.1 New Targeted Medicine Works Better and Results with Fewer Adverse Effects 31

5.4.2 Impact of Immunotherapy Continues to Grow in Slowing Advanced Cancer Growth 31

5.4.3 New Approaches in Radiation Therapy Provide Novel Treatment Options 32

5.4.4 Advances in Cancer Treatment 32

5.4.5 Availability of Novel Agents for NSCLC has Increased the Number of Treated Patients 33

5.5 Challenges 33

5.5.1 High Bar for Any New Treatment 33

5.5.2 The Scarcity of Lung Transplant Organs 33

6 LUNG CANCER THERAPEUTICS MARKET, by Type

6.1 SCLC 35

6.2 NSCLC 36

7 LUNG CANCER THERAPEUTICS MARKET, by Treatment

7.1 Surgery 38

7.2 Chemotherapy 39

7.3 Radiotherapy 40

7.4 Photodynamic Therapy (PDT) 41

7.5 Laser Therapy 42

8 LUNG CANCER THERAPEUTICS MARKET, by End-User

8.1 Hospital & Clinics 44

8.2 Cancer Research Centers 44

8.3 Laboratories 45

9 Global LUNG CANCER THERAPEUTICS MARKET, by Region

9.1 North America 47